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Should We Indeed Measure
Carotid Intima-Media Thickness
for Improving Prediction of
Cardiovascular Events After
IMPROVE?*
Michiel L. Bots, MD,† Hester M. den Ruijter, PHD,*‡
Utrecht, the Netherlands
For 3 decades, the measurement of carotid intima-media
hickness (CIMT) has been applied in cardiovascular re-
earch (1). Yet, there are still various questions regarding the
IMT measurement (2,3). Two are addressed in the report
y Baldassarre et al. (4) in this issue of the Journal: “What
is the ‘best’ CIMT measure for increased cardiovascular
risk?” and “Does a CIMT measurement help improve the
prediction of cardiovascular events?.”
See page 1489
Baldassarre et al. (4) present the results of a large cohort
study (IMPROVE [Carotid Intima Media thickness (IMT)
and IMT-PROgression as Predictors of Vascular Events in
a High-Risk European Population]) among 3,703 asymp-
tomatic subjects, age 54 to 79 years, who had at least 3
vascular risk factors. IMPROVE recruited from 7 centers in
Finland, France, Italy, the Netherlands, and Sweden.
CIMT was measured at the common and internal carotid
segments and at the carotid bifurcation, at both the near and
far wall. From these measurements, several CIMT measures
were constructed. The interadventitial lumen diameter of
the common carotid artery was also measured. Mean Fra-
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cardiovascular event) of the cohort was 22%. Subjects were
followed up for an average of 36.2 months, during which
215 cardiovascular events occurred.
What is the “best” CIMT measure for increased cardio-
vascular risk? Over the past decades, a large number of
studies have reported on the relation of increased CIMT
and increased cardiovascular risk. Most studies had only
common CIMT measurements. Some had also measure-
ments from the other segments and expressing the CIMT
measure as mean-maximum CIMT. Because the studies
used different ultrasound approaches (scanning protocols,
ultrasound equipment, and quantification methods) that
affect the value of the CIMT measure, a direct comparison
between various CIMT measures in their ability to reflect
increased cardiovascular risk could not be done validly (5).
The IMPROVE study makes this possible, however. By
using 1 common ultrasound protocol, the authors found
that for all CIMT measures (common, bifurcation, internal,
mean and maximum, and aggregated CIMT estimates), an
increased value is related to an increased risk of cardiovas-
cular disease: the increased risk per 1 SD increase in CIMT
varies between 22% and 43% (Table 3, model 4) (4).
Importantly, there are no strikingly significant differences
between the various CIMT measures in their ability to
reflect risk. Thus, a common CIMT measure seems as good
as a more elaborate CIMT measure. This finding supports
the current view that there is no carotid artery segment (i.e.,
comparison among the various segments) that has clearly
demonstrated a more significant association with cardiovas-
cular disease (6). Of course, one may argue that the current
sample (215 events) is too small to detect significant
differences in the magnitude of the relation with cardiovas-
cular event between the different CIMT measures. Thus,
just because no difference is found does not convincingly
prove that no difference exists. Unless results from larger
studies or results from pooled analyses of existing studies
show otherwise, there seems to be no compelling evidence
to suggest that combined measurements or measurement of
a specific segment is superior.
Does a CIMT measurement help improve the prediction
of cardiovascular events? Adding a measurement of
CIMT to cardiovascular risk factors has been proposed as a
strategy to improve prediction of cardiovascular risk in an
individual. So far, several studies reported on this issue, but
the evidence seems inconsistent (3). Some reported im-
provement (6) whereas others did not (7,8) or only in
subgroups or for specific cardiovascular events (9). Despite
the inconsistency, private initiatives proposing to have an
individual’s CIMT measured for adequate cardiovascular
risk assessment are rapidly emerging. Therefore, more
evidence on this issue as provided by IMPROVE is needed.
Baldassarre et al. (4) provide net reclassification improve-
ment estimates for various CIMT measures by using the
Framingham risk factors as a starting point for risk strati-
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When only the common CIMT is added to Framingham
risk variables, 80% of the population remains in the
original risk category. Approximately 5% of the individuals
were correctly reclassified. For the more elaborate CIMT
measures, 70% does not change the risk group. The
combined CIMT measure (mean-maximum) leads to cor-
rectly reclassifying 10.5% of the individuals. Adding an
interadventitial diameter measurement to the mean-
maximum CIMT measure leads to a correct reclassification
in 12% of the individuals. Table 7 (4) clearly also shows that
a considerable proportion of the reclassified individuals
(36% to 38%) was incorrectly moved to another risk cate-
gory.
Potential clinical implication of the net reclassification
improvement results. When assessing the reclassification
statistics for clinical usefulness, it is important to actually see
what happens to the individuals (who is shifted and in
which direction [lower or higher risk]) and what are the
observed risks within those groups. Table 8 provides this
crucial information for the model where mean-maximum
CIMT and interadventitial diameter were added (4). From
that table, we find that 30% of the studied population has a
Framingham risk score of 20%. One could argue whether
this group of patients should actually undergo further risk
stratification with CIMT measurements because they al-
ready qualify for pharmacological treatment, certainly in the
presence of 3 established cardiovascular risk factors. A
CIMT measurement in this group is only relevant when one
would consider refraining from pharmacological treatment
when the estimated absolute CVD risk of the individual
becomes 20%. The IMPROVE authors clearly state that
they do not favor less intensive treatment in this group and
thus implicitly tell us that further risk stratification with
CIMT in the high-risk group should not be conducted.
Others (10) also indicated that less intensive intervention
should not be advised according to ultrasound imaging data
for individuals otherwise estimated at intermediate-to-high
vascular risk on the basis of traditional vascular risk factors.
Based on the results in Table 8 (4), one could also argue
whether measurement of CIMT would be worthwhile in
the low-risk group. No individual moved from the low- to
the high-risk category.
A considerable group of individuals (14.5%) shifted from
the intermediate-risk group to the high-risk category. These
individuals had a very high extrapolated 10-year risk of
developing vascular events. In addition, the CIMT result
led to a downward classification in 1 of 5 individuals.
Unfortunately, the percentage of intermediate-risk individ-
uals who were correctly reclassified and its variance estimate
is not provided in the paper.
Where does IMPROVE bring us? IMPROVE also con-
firmed that in populations with considerable medication
use, an increased CIMT is related to increased CVD risk
(4). Furthermore, it expands the knowledge base by showingthat for such relations, common CIMT measures are as
good as more elaborate CIMT measures.
IMPROVE found that for risk classification, the more
elaborate CIMT measures are preferred above common
CIMT measures (4). This finding is concordant with some
(7–11) but not all studies (6). The Atherosclerosis Risk In
Communities studies found no difference between the
common and more elaborate CIMT measures in reclassifi-
cation ability, a result compatible with IMPROVE (6).
MPROVE seems to show that CIMT measurements for
mproving prediction of cardiovascular risk should be re-
tricted to intermediate-risk groups only, a finding that is
ongruent with most of the other studies.
IMPROVE was conducted among individuals with 3
ardiovascular risk factors (4). Its results highlight the
ilemma of less intensive (pharmacological) treatment in
hose whose estimated risk, as based on traditional risk
actors, is lowered as a consequence of the CIMT result.
his applies to individuals going from high-risk to
ntermediate-risk and for individuals with intermediate-risk
oing to low-risk and calls on the concept of treating risk rather
han risk factor levels. If we are not willing to treat risk, then
he added value of a marker in the improvement of risk
rediction should be based on upward classification only.
A number of issues remain. First, clinical trials are needed
o determine whether, in the intermediate-risk group, a
trategy of making therapeutic decisions by using CIMT in
ddition to established risk factors compared with using
stablished risk factors alone in cardiovascular disease risk
rediction will prevent cardiovascular events. In such trials,
illingness to refrain from pharmacological treatment when
own classification occurs must be taken into account.
econd, cost-effectiveness studies need to be performed to
tudy whether the estimated added value of CIMT mea-
urement translates into health benefits against which costs,
n particular for the intermediate-risk group. Finally, most
ndividual studies lack power for valid and precise specific
nalyses by age, sex, ethnicity, risk factor groups, and
ardiovascular event. Such studies are needed to identify
hose individuals in whom the benefits may be largest.
ooling of cohorts worldwide followed by individual par-
icipant data analyses may address these issues (12).
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